General use cases
- Carcinoma, Non-Small-Cell Lung
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
Home→PDE/ADE · OEL/OEB Profiles → Zidesamtinib→
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
ReguSight provides project-specific support for Zidesamtinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Zidesamtinib Permitted Daily Exposure (PDE) report (the Zidesamtinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Zidesamtinib Occupational Exposure Limit (OEL) report (the Zidesamtinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.